At a glance
ClinicalIndex Comparison Record- ✓Age >18 years
- ✓History of heartburn at least 2 days per week over the past month
- ✓Female: not of childbearing potential, or if of childbearing potential, using approved contraception with negative pregnancy test
- ✕History of erosive esophagitis verified by endoscopy
- ✕History of gastroesophageal reflux disease (GERD) diagnosed by a physician
- ✕History of Barrett's esophagus or esophageal stricture
- ✕Continuous use of proton pump inhibitors, H2 blockers, or prokinetics (intermittent prior use allowed if discontinued appropriately)
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
E3810-A001-312: Efficacy and Safety of 10 mg Rabeprazole for Treating Heartburn in Frequent Sufferers
In Brief
A Phase 3 clinical trial evaluating rabeprazole sodium and placebo for Heartburn. Completed, enrolled 619 participants across 1 site.
Detailed Summary
The purpose of this study is to investigate the safety and efficacy of rabeprazole 10 mg in treating frequent heartburn.
Study Details
Timeline
Interventions
Following a one week single-blind, placebo run-in phase, patients will receive rabeprazole 10 mg orally,placebo once daily, for 14 days during the double-blind, randomized treatment phase. This will be followed by a one week single-blind placebo follow-up phase.
Following a one week single-blind, placebo run-in phase, patients will receive placebo orally, once daily, for 14 days during the double-blind, randomized treatment phase. This will be followed by a one week single-blind placebo follow-up phase.